Short Interest in Ernexa Therapeutics Inc. (NASDAQ:ERNA) Expands By 68.8%

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 24,656 shares, an increase of 68.8% from the July 30th total of 14,605 shares. Based on an average daily trading volume, of 47,948 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.5% of the company’s shares are short sold.

Institutional Investors Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission. 70.55% of the stock is currently owned by institutional investors and hedge funds.

Ernexa Therapeutics Stock Performance

Shares of NASDAQ ERNA traded down $0.22 during midday trading on Tuesday, hitting $4.35. 29,202 shares of the stock traded hands, compared to its average volume of 808,598. The company has a market cap of $7.09 million, a PE ratio of -0.30 and a beta of 2.57. Ernexa Therapeutics has a one year low of $3.18 and a one year high of $71.50. The business has a 50 day moving average price of $5.11 and a two-hundred day moving average price of $6.48.

Ernexa Therapeutics (NASDAQ:ERNA) last issued its earnings results on Thursday, August 6th. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10). As a group, equities research analysts forecast that Ernexa Therapeutics will post -18.02 EPS for the current fiscal year.

Analysts Set New Price Targets

ERNA has been the subject of several recent analyst reports. Zacks Research raised shares of Ernexa Therapeutics to a “hold” rating in a research report on Monday, May 11th. Wall Street Zen downgraded shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. Finally, Brookline Capital Markets began coverage on shares of Ernexa Therapeutics in a report on Thursday, May 7th. They issued a “buy” rating and a $30.00 price target for the company. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Ernexa Therapeutics currently has a consensus rating of “Hold” and an average price target of $30.00.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.